NCT05946135

Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids

A Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Efficacy of Fexuprazan for the Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids (FEAST)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Yonsei University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

* This clinical trial is conducted as a double-blind, randomized, and active drug control clinical trial. If the screening results determine that the selection/exclusion criteria are met, the clinical trial drugs are randomly assigned at a 1:1 ratio of the Pexuprazan 40 mg and the Lansoprazole 15 mg dose group and taken for 4 weeks. * Gastritis symptoms are evaluated four weeks after baseline (Visit1) and clinical drug administration (Visit2), and if it is determined that gastritis is necessary according to the medical team's judgment due to gastrointestinal symptoms during the study participation period, endoscopy is performed to check whether gastritis occurs.

Conditions

• Patients on Treatment With Systemic Steroids

Interventions

Type	Name	Description
DRUG	Lansoprazole	taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks
DRUG	Fexuprazan Hydrochloride	taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks

Timeline

• Start date: 2023-11-07
• Primary completion: 2025-09-08
• Completion: 2025-09-08
• First posted: 2023-07-14
• Last updated: 2026-01-13

Locations

1 site across 1 country: South Korea